about
Daptomycin in paediatrics: current knowledge and the need for future researchNovel epigenetic target therapy for prostate cancer: a preclinical studyACTH-induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in adrenals of hypophysectomized rats is not cause-effect related to its immediate steroidogenic actionThe calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaineDrug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance.Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet.Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Towards a framework for treatment effectiveness in schizophrenia.Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors.Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatientsClinical implications of dopamine research in schizophrenia.Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective.Consensus on the use of substituted benzamides in psychiatric patients.Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification.Practical issues with amisulpride in the management of patients with schizophrenia.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation information).Association of neovascular age-related macular degeneration with month and season of birth in Italy.Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving beThe placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database.Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways.Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons: Evidence From the Italian Nationwide OsMed Health-DB Database.Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases.Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparencyThe Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
P50
Q27006038-33721202-D9B9-4B74-BD1E-D25E25A59820Q27330048-DC2F1C31-82C3-46E3-85E6-B7262375C50CQ28263856-C56893ED-EB0D-4EC8-9234-54A2A2AB9BD6Q28326470-6B5191DA-C6AB-41F5-9E86-3E5B31222CC5Q30858832-FBC95856-3868-47B1-9C76-8354ED47A9AFQ30990837-C00007C8-09C4-47ED-8060-87595D20A288Q30993551-B1D6199C-7AC0-4A3B-8C01-9D6B134E26F8Q33319037-44498792-00D0-4ED4-97B7-19CB321A3B8EQ33547147-58ECF9A8-8A75-41F0-A28B-B4240C07EFB9Q33619940-17CC1D78-72BD-41E5-9EA3-65E63B39F09BQ34274631-1221C56B-77A5-4FD3-A94A-2F911CBFBFA5Q34315361-FEED1DA0-1057-46CB-B4C2-1A19E90CF73BQ34408888-2AEF6C30-F557-4CFF-B910-500E1C5AD5E9Q34465401-86844EF9-B88F-424F-8526-936C490A76D6Q34956421-92FEB70A-146A-4C6B-9111-29ADBAF804B4Q34990191-F0978666-2FAE-4721-BE9A-B7A7AB74FAA8Q35052866-8449793B-6C48-4DEB-9019-4C3ACB9BC125Q35762997-C2FC7BA5-DDD1-44D7-A506-D9F50622ACE1Q35763872-F224EC9F-967D-4D7F-B77A-6E92E533E07BQ35855283-31CFC51E-E627-46EB-A7F3-86DCD674A0D1Q35877724-6B81145B-3FB1-49BE-8413-0E98907B3D79Q36064517-642B2D33-904A-4D6D-8449-976F30E0EBFEQ37206139-7F1CFD83-26A1-40D9-A9DD-57A052D4FB5DQ37422493-56ADF644-63AB-46B3-A656-9BAEED48066DQ37588927-C885C779-3B44-4117-B99D-A57BE7F04A5BQ37643502-47D1EA20-9E28-44B1-ABE7-10A0457190DAQ37929389-B0BCE89F-0404-4C0E-88B6-E5D27342755BQ38019212-31B8C603-F231-423B-B921-711356B01D80Q38225386-046A98F5-B389-48E9-850B-E217A8267D3AQ38379186-F159DF8C-C451-45CD-A2BE-9E50E358F5DBQ38600991-6287DFDE-5EDB-4AD8-BFFC-06B92B125FB4Q38619098-B0FA8DBC-EABA-4D00-A7CC-77CA99BB332EQ38789871-D4E84F40-FA74-4C1A-83CD-58D24B8C6B48Q38954063-14579611-82F7-4871-BB21-3A2C39426EC3Q39021867-9F237DEF-DE75-4B02-9B24-6833AB099B85Q39198633-460CFD29-9403-4148-A768-2709DD3E9387Q39339696-8F8FC835-96C8-4E38-A90C-6C05AB2A4562Q39456638-55F7C08F-2FC5-48C2-87F1-5F7B51190AF2Q40086306-E78DF29D-E4CE-4713-AE52-2B15F35169F7Q40232366-82F40963-C052-4A0E-A60A-865952F185BB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luca Pani
@ast
Luca Pani
@en
Luca Pani
@es
Luca Pani
@nl
Luca Pani
@sl
type
label
Luca Pani
@ast
Luca Pani
@en
Luca Pani
@es
Luca Pani
@nl
Luca Pani
@sl
prefLabel
Luca Pani
@ast
Luca Pani
@en
Luca Pani
@es
Luca Pani
@nl
Luca Pani
@sl
P106
P1153
55327475000
P21
P31
P496
0000-0001-9273-2839